Basilea Pharmaceutica has announced the launch of Zevtera, its lead anti-bacterial treatment, in the US by partner Innoviva Specialty Therapeutics (IST), marking a key strategic milestone for the company. Zevtera, an advanced generation IV cephalosporin antibiotic, was approved by the FDA in April

21 May 2025
Basilea Pharmaceutica:Zevtera hits the shelves in the US

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Basilea Pharmaceutica:Zevtera hits the shelves in the US
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
21 May 2025 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
2 -
Basilea Pharmaceutica has announced the launch of Zevtera, its lead anti-bacterial treatment, in the US by partner Innoviva Specialty Therapeutics (IST), marking a key strategic milestone for the company. Zevtera, an advanced generation IV cephalosporin antibiotic, was approved by the FDA in April